📊 ELTP Key Takeaways
Is Elite Pharmaceuticals Inc. /N.V./ (ELTP) a Good Investment?
Elite Pharmaceuticals demonstrates exceptional financial health with robust profitability metrics (50.2% gross margin, 36.0% operating margin, 24.4% net margin) and strong revenue growth of 48.4% YoY. The company maintains fortress-like balance sheet strength with minimal leverage (0.02x debt/equity), exceptional liquidity (7.34x current ratio), and substantial free cash flow generation of $14.1M, providing strategic flexibility for growth initiatives.
Elite Pharmaceuticals shows unusually strong operating fundamentals for a small pharmaceutical manufacturer, with 48.4% revenue growth, 36.0% operating margin, 24.4% net margin, and positive free cash flow. The balance sheet is conservatively positioned with high liquidity, minimal long-term debt, and strong interest coverage, which supports resilience. The main quality concern is that rapid sales growth did not translate into net income growth, suggesting margin mix, cost normalization, or dilution-related pressure should be monitored closely.
Why Buy Elite Pharmaceuticals Inc. /N.V./ Stock? ELTP Key Strengths
- Exceptional profitability with 50.2% gross margin and 36.0% operating margin indicating strong pricing power and operational efficiency
- Strong revenue growth of 48.4% YoY demonstrates robust market demand and successful commercialization
- Fortress balance sheet with minimal debt (0.02x debt/equity), $21.1M cash, and 7.34x current ratio providing financial flexibility
- Outstanding returns on equity (32.9%) and assets (20.9%) indicating efficient capital deployment
- Robust free cash flow of $14.1M with 13.0% FCF margin supporting sustainability of operations and potential reinvestment
- Strong top-line growth with high gross, operating, and net margins
- Excellent balance sheet quality with very low leverage and strong liquidity
- Positive operating cash flow and free cash flow generation that supports self-funded growth
ELTP Stock Risks: Elite Pharmaceuticals Inc. /N.V./ Investment Risks
- Concerning EPS decline of -100% despite flat net income suggests significant equity dilution and share issuance
- Flat net income growth (0.0% YoY) despite 48.4% revenue growth indicates margin compression or one-time charges requiring investigation
- Limited insider activity with only 1 Form 4 filing in last 90 days suggests minimal insider confidence signals
- Pharmaceutical sector regulatory and patent cliff risks could impact future revenue sustainability and profitability
- Net income was flat despite sharp revenue growth, which raises questions about earnings conversion quality
- Diluted EPS deterioration suggests potential share count dilution or non-operating pressures
- Pharmaceutical fundamentals can be sensitive to product concentration, regulatory issues, and manufacturing execution
Key Metrics to Watch
- Net income growth trajectory relative to revenue growth to assess margin sustainability
- EPS recovery and share dilution trends to understand capital structure changes
- Free cash flow consistency and conversion from operating cash flow
- Gross margin stability amid competitive pricing pressures
- Debt levels and capital allocation decisions for shareholder returns
- Net income and diluted EPS conversion relative to revenue growth
- Operating cash flow and free cash flow consistency as sales scale
Elite Pharmaceuticals Inc. /N.V./ (ELTP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.34x current ratio provides a solid financial cushion.
ELTP Profit Margin, ROE & Profitability Analysis
ELTP vs Healthcare Sector: How Elite Pharmaceuticals Inc. /N.V./ Compares
How Elite Pharmaceuticals Inc. /N.V./ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Elite Pharmaceuticals Inc. /N.V./ Stock Overvalued? ELTP Valuation Analysis 2026
Based on fundamental analysis, Elite Pharmaceuticals Inc. /N.V./ appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Elite Pharmaceuticals Inc. /N.V./ Balance Sheet: ELTP Debt, Cash & Liquidity
ELTP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Elite Pharmaceuticals Inc. /N.V./'s revenue has grown significantly by 161% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.02 reflects profitable operations.
ELTP Revenue Growth, EPS Growth & YoY Performance
ELTP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $14.4M | $615.8K | $-0.01 |
| Q2 2026 | $18.9M | $615.8K | $-0.01 |
| Q1 2026 | $18.8M | $615.8K | $0.00 |
| Q3 2025 | $14.4M | $615.8K | $0.00 |
| Q2 2025 | $14.2M | $615.8K | $0.01 |
| Q1 2025 | $9.0M | $615.8K | $0.00 |
| Q3 2024 | $9.3M | $305.9K | $0.00 |
| Q2 2024 | $8.6M | $305.9K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Elite Pharmaceuticals Inc. /N.V./ Dividends, Buybacks & Capital Allocation
ELTP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Elite Pharmaceuticals Inc. /N.V./ (CIK: 0001053369)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELTP
What is the AI rating for ELTP?
Elite Pharmaceuticals Inc. /N.V./ (ELTP) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELTP's key strengths?
Claude: Exceptional profitability with 50.2% gross margin and 36.0% operating margin indicating strong pricing power and operational efficiency. Strong revenue growth of 48.4% YoY demonstrates robust market demand and successful commercialization. ChatGPT: Strong top-line growth with high gross, operating, and net margins. Excellent balance sheet quality with very low leverage and strong liquidity.
What are the risks of investing in ELTP?
Claude: Concerning EPS decline of -100% despite flat net income suggests significant equity dilution and share issuance. Flat net income growth (0.0% YoY) despite 48.4% revenue growth indicates margin compression or one-time charges requiring investigation. ChatGPT: Net income was flat despite sharp revenue growth, which raises questions about earnings conversion quality. Diluted EPS deterioration suggests potential share count dilution or non-operating pressures.
What is ELTP's revenue and growth?
Elite Pharmaceuticals Inc. /N.V./ reported revenue of $108.1M.
Does ELTP pay dividends?
Elite Pharmaceuticals Inc. /N.V./ does not currently pay dividends.
Where can I find ELTP SEC filings?
Official SEC filings for Elite Pharmaceuticals Inc. /N.V./ (CIK: 0001053369) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELTP's EPS?
Elite Pharmaceuticals Inc. /N.V./ has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELTP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Elite Pharmaceuticals Inc. /N.V./ has a BUY rating with 84% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ELTP stock overvalued or undervalued?
Valuation metrics for ELTP: ROE of 32.9% (sector avg: 15%), net margin of 24.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ELTP stock in 2026?
Our dual AI analysis gives Elite Pharmaceuticals Inc. /N.V./ a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ELTP's free cash flow?
Elite Pharmaceuticals Inc. /N.V./'s operating cash flow is $14.6M, with capital expenditures of $527.6K. FCF margin is 13.0%.
How does ELTP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 24.4% (avg: 12%), ROE 32.9% (avg: 15%), current ratio 7.34 (avg: 2).
Why is ELTP's return on equity (ROE) so high?
Elite Pharmaceuticals Inc. /N.V./ has a return on equity of 32.9%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 24.4% net margin.